Anavex Life Sciences Corp (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company that discovers and develops drug candidates targeting neurological and other diseases. The company generates no product revenue; it is funded through equity issuances, including at-the-market offerings under a Sales Agreement with TD Securities (USA) LLC that permits sales of up to $150 million in common stock (entered July 25, 2025), and previously through a 2023 Purchase Agreement that provided $11.3 million in fiscal 2024. All spending is directed toward research and development and general and administrative costs, with R&D expenses declining year over year in fiscal 2025 while general and administrative expenses rose to $13.8 million (versus $11.0 million in fiscal 2024), driven by $1.7 million in higher legal fees. Key pipeline candidates include ANAVEX3-71, with Part B of the ANAVEX3-71-SZ-001 trial completing in fiscal 2025. Competitors are larger pharmaceutical and biotechnology companies with greater capital, larger R&D staffs, and more extensive regulatory and manufacturing experience.

Revenue model

No product revenue as of fiscal year ended September 30, 2025. Operations are financed through equity issuances via at-the-market offerings and purchase agreements. Net other income was $5.0 million in fiscal 2025, down from $9.9 million in fiscal 2024.

Products and services

Pipeline drug candidates including ANAVEX3-71 (evaluated in the ANAVEX3-71-SZ-001 trial, with Part B completing in fiscal 2025). The company also has candidates associated with Rett syndrome clinical trials referenced in ongoing litigation. No products are approved or commercialized as of the fiscal year ended September 30, 2025.

Customers and end markets

No commercial customers as of fiscal year ended September 30, 2025. End markets targeted include neurological diseases. Clinical trial participants are enrolled through contract research organizations and clinical sites.

Value-chain role

Drug discovery and clinical-stage development company. Relies on third-party contract research organizations, university laboratories, and clinical sites for trial execution. Manufacturing is outsourced; costs are expensed as incurred under ASC 730.

Geographic exposure

Incorporated and operating with U.S. securities filings; specific geographic revenue or operational breakdown is not disclosed in the excerpts provided.

Source: SEC 10-K, filed 2025-11-25

Industry: Biological Products, (No Diagnostic Substances) Peers: Kalaris Therapeutics Inc AnaptysBio Inc Coherus Oncology Inc Dyne Therapeutics, Inc RAPT Therapeutics, Inc. Northwest Biotherapeutics Inc Sorrento Therapeutics, Inc. Sangamo Therapeutics Inc Seres Therapeutics Inc